Cell · 2026
Copper ion-induced MYH9 polymerization executes cuproptosis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wu Liu-Zheng, Mi Xiang-Yu, Liu Zai-Jun, Ding Yang, Hong Wen-Bin, Cai Chen-Xi, Hu Hai-Jing, Ai Yuan-Li, Zhao Bi-Xing, Qiu Duo-Duo, Ma Jing-Song, Chen Xue-Qin, You Han, Lin Tianwei, Li Fu-Nan, Hong Xue-Hui, Chen Hang-Zi, Wu Qiao
Аннотация
Cuproptosis is a recently identified form of copper-dependent cell death implicated in various physiological and pathological processes. However, the executive proteins involved and the role of physiological intracellular copper in cuproptosis remain unclear. Herein, we identified myosin heavy-chain 9 (MYH9) as a cuproptosis executioner. Copper binding induced MYH9 polymerization, which disrupted the actin cytoskeleton and led to cuproptotic cell death. Hexyl 2-(3,4,5-trihydroxy-phenyl) acetate (HThPA) was shown to induce cuproptosis by binding to the nuclear receptor Nur77, leading to depletion of copper chelate glutathione (GSH) and release of free copper from intracellular copper stores. Acetylation of MYH9 by acetyltransferase dihydrolipoamide S-acetyltransferase (DLAT) facilitated copper binding, regardless of its extracellular or intracellular origin. Physiological copper levels were higher in drug-resistant tumor cells and clinical samples, which increased the likelihood of HThPA-induced cuproptosis. These results elucidate the mechanisms underlying cuproptosis, establish MYH9 as an executioner, and propose a treatment strategy for drug-resistant tumors.